| Molecular Formula | C9H4N4O4 |
| Molar Mass | 232.15 |
| Density | 1.5507 (rough estimate) |
| Melting Point | 300 °C |
| Boling Point | 374.31°C (rough estimate) |
| Solubility | H2O: 10mg/mL |
| Appearance | solid |
| Color | orange to red |
| pKa | 8.16±0.20(Predicted) |
| Storage Condition | protect from light |
| Stability | Store Tightly Sealed at RT |
| Refractive Index | 1.6590 (estimate) |
| In vitro study | CNQX (FG9065; 2-5 μM) reversibly blocks the Schaffer collateral and mossy fibre excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition in superfusion of hippocampal slices. CNQX (1-5 μM) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments. |
| In vivo study | CNQX (FG9065; 2-5 μM) reversibly blocks the Schaffer collateral and mossy fibre excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition in superfusion of hippocampal slices. CNQX (1-5 μM) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments. Animal Model: Male Wistar rats weighing 180-200 g Dosage: 0.75, 1.5, and 3 mg/kg Administration: IP; 20 min before testing Result: Decreased the number of cocaine (IV; 0.25 mg/infusion) responses in a dose-dependent manner during the first 15-min cocaine-free interval |
| Hazard Symbols | Xi - Irritant![]() |
| Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. |
| WGK Germany | 3 |
| RTECS | VD1520000 |
| HS Code | 29335990 |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 4.308 ml | 21.538 ml | 43.076 ml |
| 5 mM | 0.862 ml | 4.308 ml | 8.615 ml |
| 10 mM | 0.431 ml | 2.154 ml | 4.308 ml |
| 5 mM | 0.086 ml | 0.431 ml | 0.862 ml |
| biological activity | CNQX (FG9065) is an effective competitive AMPA/alginate receptor (AMPA/kainate receptor) antagonist, IC50 is 0.3 μM and 1.5 μM respectively. CNQX is a competitive non-NMDA receptor antagonist. CNQX blocks the expression of fear enhancement in rats. |
| target | IC50: 0.3 μM (AMPA) and 1.5 μM (kainate receptor) |
| in vitro research | CNQX (FG9065; 2-5μM) reversibly blocks the Schaffer collateral and mossy fiber excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition in superfusion of hippocampal slices. CNQX (1-5μM) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments. |
| in vivo research | CNQX (FG9065; 2-5μ M) reversibly blocks the Schaffer collateral and mossy fiber excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition in superfusion of hippocampal slices. CNQX (1-5μ M) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments. Animal Model: Male Wistar weighing 180-200g Dosage: 0.75, 1.5, and 3 mg/kg Administration: IP; 20 min before testing Result: Decreased the number of cocaine (IV; 0.25 mg/infusion) responses in a dose-dependent manner during the first 15-min cocaine-free interval |
| Animal Model: | Male Wistar rats weighing 180-200g |
| Dosage: | 0.75, 1.5, and 3 mg/kg |
| Administration: | IP; 20 min before testing |
| Result: | Decreased the number of cocaine (IV; 0.25 mg/infusion) responses in a dose-dependent manner during the first 15-min cocaine-free interval |